B
Bull
Bull · 25%ALC
$97.66
Scenario price
$72.010
-0.216 (-0.30%)At close
Loading chart…
- High
- 72.070
- Open
- 71.690
- VWAP
- 71.82
- Vol
- 1.18M
- Mkt Cap
- 44.25B
- Low
- 71.380
- Amount
- 84.53M
- EV/EBITDA, TTM
- 13.83
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries.
AI analysis of Alcon AG (ALC)
holdAlcon AG (ALC) is currently priced at $72.01, which is below the average analyst price target of $79 to $85. However, the stock has a low RSI of 37.964, indicating it may be oversold, but the recent earnings report showed a significant drop in net income to $0.00 in Q2 2026, which raises concerns. The main risk is the downgrade from BNP Paribas, which reflects a challenging outlook for the company in the near future.
Valuation Metrics
The current forward P/E ratio for Alcon AG (ALC) is 20.66, compared to its 5-year average forward P/E of 27.56.
Alphio AI Price Scenarios for ALC
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding ALC
Events Timeline
News
9.508-10NewsfilterAlcon Reports $2.8 Billion in Q2 2026 Sales, Up 8%
9.508-09CNBCInflation Data and Market Dynamics Preview
7.507-07NASDAQ.COMAlcon Partners with RxSight to Develop Adjustable Intraocular Lenses
- 8.507-06Yahoo Finance
Alcon and Mexican Gold Finalize Arrangement Agreement
7.507-06GlobenewswireAlcon and RxSight Collaborate on Adjustable Intraocular Lens Development
ALC FAQ — answered by Alphio AI
Alcon AG is a Switzerland-based eye care company. The Company research, develop, manufacture, distribute and sell a full suite of eye care products within two key businesses: Surgical and Vision Care. The Company’s Surgical business is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery. The surgical portfolio includes implantables, consumables and surgical equipment required for these procedures and supports the end-to-end needs of the ophthalmic surgeon. The Company’s Vision Care business comprises of daily disposable, reusable and color-enhancing contact lenses and a portfolio of ocular health products, including products for dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The Company operates in 60 countries and serves consumers and patients in over 140 countries. It operates in the Healthcare sector.
Alcon AG (ALC) is currently priced at $72.01, which is below the average analyst price target of $79 to $85. However, the stock has a low RSI of 37.964, indicating it may be oversold, but the recent earnings report showed a significant drop in net income to $0.00 in Q2 2026, which raises concerns. The main risk is the downgrade from BNP Paribas, which reflects a challenging outlook for the company in the near future.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.